The interface between coagulation and immunity

American Journal of Transplantation

Volumn 7, Issue 3, 2007, Pages 499-506

  Shrivastava, S ^a   McVey, J H ^a   Dorling, A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Rejection; Thrombin; Tissue factor

Indexed keywords

CALCIUM IONOPHORE; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FAMILY; SERUM RESPONSIVE ELEMENT; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSPLANTATION; XENOTRANSPLANTATION;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; GRAFT SURVIVAL; HUMANS; IMMUNITY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MICE; ORGAN TRANSPLANTATION; PEPTIDE HYDROLASES; RECEPTORS, THROMBIN; THROMBIN; THROMBOSIS;

EID: 33847745865     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01653.x     Document Type: Short Survey

References (75)

1. McVey JH. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol 1999; 12: 361-372.
2. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
3. Rose AG, Cooper DK. Venular thrombosis is the key event in the pathogenesis of antibody-mediated cardiac rejection. Xenotransplantation 2000; 7: 31-41.
4. Chen D,Weber M, McVey JH et al. Complete Inhibition of acute humoral rejection using regulated expression of membranetethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4: 1958-1963.
5. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 2005; 105: 2384-2391.
6. Chackalamannil S. Thrombin receptor antagonists as novel therapeutic targets. Curr Opin Drug Discov Dev 2001; 4: 417-427.
7. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-23366.
8. Polgar J, Matuskova J,Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 3: 1590-1596.
9. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-461.
10. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 12020-12028.
11. MacGregor IR, Perrie AM, Donnelly SC, Haslett C. Modulation of human endothelial thrombomodulin by neutrophils and their release products. Am J Respir Crit Care Med 1997; 155: 47-52.
12. Gu JM, Katsuura Y, Ferrell GL,Grammas P, Esmon CT. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNAlevels and increase receptor shedding in vivo. Blood 2000; 95: 1687-1693.
13. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR, Bach FH, Dalmasso AP. Release of heparan sulphate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363-1368.
14. Chen D, Giannopoulos K, Shiels PG et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood 2004; 104: 1344-1349.
15. Chen D, Dorling A. Microcoagulation processes after xenotransplantation. Curr Opin Organ Transplant 2005; 10: 240-245.
16. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-5260.
17. Warr TA, Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489.
18. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB, Jr., Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2856.
19. Levi M, Cate H, Bauer KA et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
20. Biemond BJ, Levi M, Cate H et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995; 73: 223-230.
21. Dackiw AP, McGilvray ID, Woodside M, Nathens AB, Marshall JC, Rotstein OD. Prevention of endotoxin-induced mortality by antitissue factor immunization. Arch Surg 1996; 131: 1273-1278.
22. Akahane K, Okamoto K, Kikuchi M et al. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide- induced endotoxemia in rats. Surgery 2001; 130: 809-818.
23. Taylor FBJ, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
24. Pawlinski R, Pedersen B, Schabbauer G et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004; 103: 1342-1347.
25. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
26. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-247.
27. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878.
28. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000; 191: 455-462.
29. Howell DC, Johns RH, Lasky JA et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycininduced lung inflammation and fibrosis. Am J Pathol 2005; 166: 1353-1365.
30. Ferrell WR, Lockhart JC, Kelso EB et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 2003; 111: 35-41.
31. Colvin RB, Mosesson MW, Dvorak HF. Delayed-type hyper-sensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest 1979; 63: 1302-1306.
32. Sun H, Ringdahl U, Homeister JW et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305: 1283-1286.
33. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-1904.
34. Fan ST, Edgington TS. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 1993; 150: 2972-2980.
35. Whitlock BB, Gardai S, Fadok V, Bratton D, Henson PM. Differential roles for alpha(M)beta(2) integrin clustering or activation in the control of apoptosis via regulation of akt and ERK survival mechanisms. J Cell Biol 2000; 151: 1305-1320.
36. Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, Altieri DC. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc Natl Acad Sci USA 1995; 92: 1505-1509.
37. Pluskota E, D'Souza SE. Fibrinogen interactions with ICAM-1 (CD54) regulate endothelial cell survival. Eur J Biochem 2000; 267: 4693-4704.
38. Sans E, Delachanal E, Duperray A. Analysis of the roles of ICAM-1 in neutrophil transmigration using a reconstituted mammalian cell expression model: Implication of ICAM-1 cytoplasmic domain and Rho-dependent signaling pathway. J Immunol 2001; 166: 544-551.
39. Martinez J, Ferber A, Bach TL, Yaen CH. Interaction of fibrin with VE-cadherin. Ann N Y Acad Sci 2001; 936: 386-405.
40. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-2894.
41. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomaterials. J Exp Med 1993; 178: 2147-2156.
42. Lu H, Smith CW, Perrard J et al. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. J Clin Invest 1997; 99: 1340-1350.
43. Wu X, Helfrich MH, Horton MA, Feigen LP, Lefkowith JB. Fibrinogen mediates platelet-polymorphonuclear leukocyte cooperation during immune-complex glomerulonephritis in rats. J Clin Invest 1994; 94: 928-936.
44. Colognato R, Slupsky JR, Jendrach M, Burysek L, Syrovets T, Simmet T. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003; 102: 2645-2652.
45. Fields RC, Schoenecker JG, Hart JP, Hoffman MR, Pizzo SV, Lawson JH. Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol 2003; 162: 1817-1822.
46. Broussas M, Cornillet-Lefebvre P, Bernard J, Adjizian JC, Potron G, Nguyen P. Separation of dendritic cells from highly purified human monocytes by counterflow centrifugation induces tissue factor expression. Transfusion 2000; 40: 1088-1094.
47. Tordai A, Fenton JW, 2nd, Andersen T, Gelfand EW. Functional thrombin receptors on human T lymphoblastoid cells. J Immunol 1993; 150: 4876-4886.
48. Hou L, Howells GL, Kapas S, Macey MG. The protease-activated receptors and their cellular expression and function in blood-related cells. Br J Haematol 1998; 101: 1-9.
49. Naldini A, Carney DH, Bocci V et al. Thrombin enhances T cell proliferative responses and cytokine production. Cell Immunol 1993; 147: 367-377.
50. Mari B, Imbert V, Belhacene N et al. Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. J Biol Chem 1994; 269: 8517-8523.
51. Bar-Shavit R, Maoz M, Yongjun Y, Groysman M, Dekel I, Katzav S. Signalling pathways induced by protease-activated receptors and integrins in T cells. Immunology 2002; 105: 35-46.
52. Shapira OM, Rene H, Lider O, Pfeffermann RA, Shemin RJ, Cohen IR. Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin. J Surg Res 1999; 85: 83-87.
53. Aramaki O, Takayama T, Yokoyama T et al. High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells. Transplantation 2003; 75: 217-220.
54. Zuo XJ, Nicolaidou E, Okada Y, Toyoda M, Jordan SC. Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. Transpl Immunol 2001; 9: 1-6.
55. Chan CW, Kay LS, Khadaroo RG et al. Soluble fibrinogen-like protein 2(fibroleukin exhibits immunosuppressive properties: Suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol 2003; 170: 4036-4044.
56. Hancock WW, Szaba FM, Berggren KN et al. Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Natl Acad Sci USA 2004; 101: 3005-3010.
57. Ning Q, Sun Y, Han M et al. Role of fibrinogen-like protein 2 prothrombinase(fibroleukin in experimental and human allograft rejection. J Immunol 2005; 174: 7403-7411.
58. Moberg L, Johansson H, Lukinius A et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039-2045.
59. Bennet W, Sundberg B, Lundgren T et al. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: Protective effects of sCR1 and heparin. Transplantation 2000; 69: 711-719.
60. Robson SC, Cooper DK, d'Apice AJ. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000; 7: 166-176.
61. Smolenski R, Kochan Z, Karbowska J et al. Low expression of ecto-5′-nucleotidase in the pig heart - a potential barrier to xenotransplantation. J Heart Lung Transplant 2001; 20: 214-215.
62. Hobson RW, Neville R,Watanabe B, Canady J, Wright JG, Belkin M. Role of heparin in reducing skeletal muscle infarction in ischemia- reperfusion. Microcirc Endothelium Lymphatics 1989; 5: 259-276.
63. Erlich JH, Boyle EM, Labriola J et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-1862.
64. Matsuyama M, Yoshimura R, Akioka K et al. Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury. Transplantation 2003; 76: 786-791.
65. Hashimoto K, Nishizaki T, Yoshizumi T et al. Beneficial effect of FR167653 on cold ischemia/reperfusion injury in rat liver transplantation. Transplantation 2000; 70: 1318-1322.
66. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96: 2302-2310.
67. Chen D, Weber M, Lechler RI, Dorling A. NK cell-dependent acute xenograft rejection in the mouse heart-to-rat model. Xenotransplantation 2006; 13: 408-414.
68. Grandaliano G, Di Paolo S, Monno R et al. Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: The role of coagulation and fibrinolysis in renal graft fibrosis. Transplantation 2001; 72: 1437-1443.
69. Holschermann H, Bohle RM, Zeller H et al. In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am J Pathol 1999; 154: 211-220.
70. Yamani MH, Masri CS, Ratliff NB et al. The role of vitronectin receptor (alphavbeta3) and tissue factor in the pathogenesis of transplant coronary vasculopathy. J Am Coll Cardiol 2002; 39: 804-810.
71. Yen MH, Pilkington G, Starling RC et al. Increased tissue factor expression predicts development of cardiac allograft vasculopathy. Circulation 2002; 106: 1379-1383.
72. Holschermann H, Bohle RM, Schmidt H et al. Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 2000; 102: 357-363.
73. Wang Y, Pratt JR, Hartley B, Evans B, Zhang L, Sacks SH. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int 1997; 52: 371-377.
74. Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-384.
75. Chen D,Weber M, Shiels PG et al. Post-injury vascular intimal hyperplasia in mice is completely inhibited by CD34+bone marrowderived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. J Thromb Haemost 2006; 4: 2191-2198.